

BEYOND SCREENING

TruScreen's news from around the globe




TRUSCREEN FEATURED AT WHO CO-HOSTED AFRICA HEALTH CARE SUMMIT

Summit hosted in Rwanda and co-hosted by the World Health Organisation (WHO), Africa Centres for Disease Control and Prevention (Africa CD) and Smart Africa

TruScreen's Rwandan representative, Charles Nshimiyimana of Biotech Medical Supply (BMS) was invited to present TruScreen at the Cervical Cancer plenary session of the Africa Health Tech Summit held in Kigali from 30 Sep-2 Oct. The summit brought together more than 4,000 delegates from across Africa and beyond, including government leaders, health professionals, technology innovators, investors and key Non Government and Government organisations including WHO and Africa CDC, and Ministry of Health officials from across Africa.

As well as presenting at the Plenary Session, Charles met the Rwanda Minister of Health Dr Sabin Nanzimana and discussed TruScreen with him. The Minister has arranged for two key Medical Advisors from his department to introduce TruScreen to their Expert Panel, and BMS is also organizing a meeting with Rwanda Biomedical Centre (RBC), the organization that implements the public health programs of Rwanda.



NEWS FROM AROUND THE GLOBE....


EAST AFRICA



- **TruScreen CEO Keynote Speaker at inaugural Kenya-Australia Trade and Investment Summit**
- **TruScreen African Footprint Expanded with Appointment of Distributor for Kenya, Somalia and South Sudan**

On 11 September, TruScreen CEO Marty Dillon was an invited keynote speaker at the Inaugural Kenya-Australia Trade and Investment Summit in Sydney. Guests included the Kenya High Commissioner, Federal and NSW cabinet members, business and academic leaders and members of the Kenyan Community - including the Hon Bishop Jackson Kipkemoi Kosgei MP (Head of Delegation) and Hon Beatrice Chepng'eno Kemei MP who has a mandate that includes advocacy on gender equality, youth, children, social protection and community-development.

Following quickly from the Summit, TruScreen expanded its African footprint with the appointment of Ansell Pharmaceuticals Limited as our distributor for Kenya, Somalia and South Sudan. Ansell's 25 member team is experienced in the supply of pharmaceuticals and medical devices to NGOs, including WHO and the UN, for NGO funded public health programs in East Africa.



L-R: Marlene Ayiro, Principal Legal Counsel – Kenya National Assembly; Timothy Kipchumba Toroitich MP Marakwet West Constituency; Beatrice Chepng'eno Kemei MP, Woman Representative Kericho County; Marty Dillon; Ruth Nduta Kamau, Organising Committee



L-R: Associate Professor David Mickler, Curtin University; His Excellency Ambassador Dr Wilson Kogo, Kenya High Commissioner to Australia; Hon. Anoulack Chanthivong, MP, Minister for Industry and Trade, Minister for Innovation, Science and Technology, NSW; Marty Dillon

ZIMBABWE



Following much bureaucratic wrangling, the year's first screening program for 10,800 women in Masvingo Province is expected to commence in 16 public hospitals in November 2026, with a second program already in discussion with our distributor.

AFRICAN GRANT APPLICATIONS

TruScreen is still under consideration for several major grants and programs. The largest of these are the Clinton Health Access Initiative application covering Sub-Saharan Africa and the UNITAID application (championed by a leading African NGO) also for Sub-Saharan Africa. In addition TruScreen is awaiting the outcome of a Nigeria-specific application for the Beginning Investigator Grant for Catalytic Research (BIG Cat), supported by American Association for Cancer Research, submitted by Dr Ayokunle Olumodeji from Lagos State University Teaching Hospital who is assisting in the preparation of applications for two more grants for programs in Nigeria.

NEWS FROM AROUND THE GLOBE....

UZBEKISTAN

TruScreen's clinical validation program in Tashkent has been completed and preliminary results have been reported as 'very good'. Final publication of the results will clear the path for public health adoption of TruScreen in Uzbekistan.

Following this news Albatros Health Care LLC, TruScreen's distributor in Uzbekistan has placed their **first order of 2,160 SUS, to be delivered this month.**


CHINA

China's South and West China Rollout Strategy begins

TruScreen's China distributor, SiWeiXiangTai Technology (SWXT) has commenced a major campaign to bring TruScreen to key Southern and Western markets. Especially important is their focus on Sichuan province which now serves as the national role model for Gynaecological products inclusion in national public hospital catalogues. The lead gynaecologist in Sichuan province is a significant supporter of TruScreen and was involved in the landmark COGA study which demonstrated TruScreen's superiority as a cervical cancer screening technology. The West China Second University Hospital of Sichuan University, the most prominent gynaecology centre in Sichuan and one of the best OBGYN hospitals in the country, is preparing a formal submission for TruScreen to be included in the public hospital catalogue.

In the South, Guangdong Province is the most important market for TruScreen's growth. In October, our distributor SWXT will sponsor the key OBGYN conference in Shantou City, and one of the major hospitals in the province, The Third Affiliated Hospital, Sun Yat-sen University, will start a clinical study on TruScreen involving 500 women. SWXT's activities are bearing fruit as two new hospitals have recently received approval to install TruScreen and a further two key hospitals have applied for and are awaiting approval to install TruScreen.

In the North in Jilin Province, TruScreen has been included in the provincial hospital catalogue and attained pricing approval. This will support the Sichuan application by acting as another strong reference for national catalogue inclusion, which will accelerate TruScreen's national roll out in China.



NEWS FROM AROUND THE GLOBE....

INDIAN SUBCONTINENT EXPANSION

A cohesive strategic approach is being developed for TruScreen expansion across the Indian subcontinent, with TruScreen executive Sumaya Mozumder taking on the role of TruScreen's dedicated regional account manager. We have been working with Austrade to build key relationships in the region with our Indian distributor, Renovate Biologicals, as well as exploring collaborative opportunities with major NGOs including PATH (Program for Appropriate Technologies in Health) in India. Indian product registration is expected to be obtained in October or November, with our distributor Renovate Biologicals preparing for an imminent product launch in the world's most populous country and fourth largest economy.



BANGLADESH



In addition to the Shariaptur Development Society grant application featured in our last newsletter, TruScreen's local distributor in Bangladesh - Xerox Medica Ltd - has engaged in talks with the Bangladesh Ministry of Health regarding additional programs utilising TruScreen's unique AI enabled technology. The proposed projects will be funded by the Bangladesh government and NGO's including the World Bank and the Asia Development Bank.

NEPAL



Nova Biointermedicx Pvt Ltd has been appointed as the TruScreen distributor for Nepal. Nova Biointermedicx has extensive connections across Nepal's Central and Provincial governments. Nova selected TruScreen as their preferred technology after comparing TruScreen to competitors for cervical cancer screening available on the local market, and chose TruScreen to participate in the upcoming government tender which opens in November. Nova is adamant that TruScreen offers the ideal solution to the problems in cervical cancer screening in Nepal where the government is striving to achieve the 70% screening coverage goal committed with WHO.



DID YOU KNOW?

TruScreen has saved over 72,000* lives - enough to fill an international football stadium.

That's the number of women who have received an abnormal TruScreen result and been referred for triage or treatment before their disease could silently progress to cancer.

**based on an average global abnormality rate of 6%.*

1,128,000


REASSURED

Received an immediate normal result. No painful biopsy, no anxious waiting for results.

72,000

Abnormal

Identified for triage or treatment before disease progresses silently.



NEWS FROM HQ...

Learn more about:

Dr Carolina Velasquez MBBS, M ClinRes

TruScreen's Medical Affairs and Training Manager

Dr Carolina Velasquez holds a Bachelor of Medicine and Surgery from Pontificia Universidad in Colombia and a Masters in Clinical Research from Monash University in Melbourne.

Multi lingual, she has 8 years experience with TruScreen conducting and supervising clinical trials in Australia, India, Zimbabwe, China, Vietnam, Indonesia and Mexico as well as overseeing all TruScreen user training across the globe.

Dr Velasquez also co-ordinates the work of both Truscreen's Medical Advisory Committee and international Medical Experts Group.



Follow us:



Get in touch: info@truscreen.com



truscreen.com